Publication

No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost

Quantitative systems pharmacology (QSP) models generate predictions by formalizing biological understanding and integrating multiscale data,…

CertaraNovember 16, 2023

Publication

Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.

Learn how eGFR strongly influences rivaroxaban clearance; PopPK modelling supports renal‑based dose reductions using Phoenix…

CertaraNovember 11, 2023

Blog

The “animal rule” – what if a clinical trial simply isn’t ethical?

Clinical trials always pose a challenge to demonstrating a drug’s safety and efficacy. Sometimes, the…

CertaraNovember 10, 2023

Press Release

Certara Reports Third Quarter 2023 Financial Results

Reiterates Full Year 2023 Financial Guidance PRINCETON, N.J.— November 8, 2023-- Certara, Inc. (Nasdaq: CERT), a…

CertaraNovember 8, 2023

On-Demand Webinar

Are Gaps in Your Clinical Pharmacology Program Jeopardizing Your Drug’s Approval?

Clinical pharmacology information comprises more than 50% of a drug label. Inadequate clinical pharmacology development…

CertaraNovember 7, 2023

On-Demand Webinar

Strategy to overcome clinical pharmacology challenges for regulatory approvals [APAC Webinar]

Clinical pharmacology information comprises more than 50% of a drug label. Inadequate clinical pharmacology development…

CertaraNovember 6, 2023

Blog

Why are medicinal chemists reluctant to use AI/ML tools?

There is a lot of current chatter about how AI/ML tools like ChatGPT will soon…

CertaraNovember 2, 2023

Blog

Overcoming medicinal chemists’ reluctance to use AI/ML tools

AI/ML tools in drug discovery, concerns about data quality and availability, interpretability of decision-making, and…

CertaraNovember 2, 2023

Announcement

Certara Recognized as 2023 Employer of Choice

PRINCETON, N.J.— November 1 2023, Certara (Nasdaq: CERT), a global leader in biosimulation, today announced…

CertaraNovember 1, 2023

Press Coverage

Using QSP Modeling to Advance Knowledge and Therapeutics for Alzheimer’s and Parkinson’s Disease

CertaraOctober 30, 2023

No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost

Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.

The “animal rule” – what if a clinical trial simply isn’t ethical?

Certara Reports Third Quarter 2023 Financial Results

Are Gaps in Your Clinical Pharmacology Program Jeopardizing Your Drug’s Approval?

Strategy to overcome clinical pharmacology challenges for regulatory approvals [APAC Webinar]

Why are medicinal chemists reluctant to use AI/ML tools?

Overcoming medicinal chemists’ reluctance to use AI/ML tools

Certara Recognized as 2023 Employer of Choice

Using QSP Modeling to Advance Knowledge and Therapeutics for Alzheimer’s and Parkinson’s Disease

Newsletter sign up

Quick links

Solutions

Contact